The fixed-effects meta-analysis indicated inhibiting the IL-6 signaling pathway can reduce the risk of NAFLD [OR = 1.80 (1.26, 2.57)]. Here, IL6 is linked to metabolic dysfunction-associated steatotic liver disease.